In the global dermatology therapeutics market in 2009, the US led with an approximate 52% market share of around $5.2 billion. Europe and Japan followed with approximate shares of 39% and 9% respectively. The US is estimated to maintain a market share of around 52% throughout the forecast period.
Request your free sample pages
There are approximately more then 700 drugs in the dermatology pipeline and with around 25 new drug licensing agreements, it is evident that the dermatology therapeutics sector is on an enormous growth path. Most licensing agreements took place in dermatitis, psoriasis and general dermatology and combined accounted for a share of 60% of overall licensing agreements.
GBI Research's new report "The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues" provides an in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the UK, Germany, France, Italy, Spain and Japan. The report provides an analysis on treatment usage patterns and sales are forecast until 2016 for the key geographies, as well as a select few therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that are shaping the global market.
# # #
The Global Markets Direct Pharma Report Store features thousands of high quality company and market research reports within the Pharmaceuticals industry.